Table 3. Spearman correlation analysis of Met content, pMet content, Gleason score and clinical T and N stage for patient tumor samples1 in the prostate adenocarcinoma (PRAD) TCGA Provisional dataset.
Parameter | Met2 vs Gleason3 | pMet2 vs Gleason3 | Met vs T stage4 | pMet vs T stage4 | Met vs N stage5 | pMet vs N stage5 |
---|---|---|---|---|---|---|
Number of XY Pairs | 352 | 352 | 348 | 348 | 309 | 309 |
Spearman r | -0.1458 | 0.03617 | -0.1503 | 0.07766 | -0.1460 | 0.08555 |
95% confidence interval | -0.2495 to -0.03875 | -0.07173 to 0.1432 | -0.2544 to -0.04278 | -0.03084 to 0.1843 | -0.2565 to -0.03163 | -0.02962 to 0.1985 |
P value (two-tailed) | 0.0061 | 0.4988 | 0.0050 | 0.1483 | 0.0102 | 0.1335 |
1All tissue samples in the PRAD TCGA RPPA Provisional cohort (n = 352) are primary prostate tumor samples
2Content scores determined by RPPA analysis
3N values for each Gleason score subgroup, from 6 to 10, are shown in Fig 2B
4N values for each T stage subgroup, from T2a to T4, are shown in Fig 2A; stage data for 4 cases was unavailable
5The N0 subgroup contained 246 cases, the N1 subgroup, 62 cases